Redcliffe Labs, a leading omnichannel diagnostics service provider, has successfully raised $42 million in its latest Series C funding round. The round was spearheaded by Denmark-based investment firm IFU, which contributed $20 million, while existing investor Leapfrog invested an additional $15 million. Other participants in this round included shareholders Health Quad and Spark Growth Ventures.
Expansion and Growth Plans
The funds from this round will be crucial in fueling Redcliffe Labs’ expansion, particularly in strengthening its presence across tier II and III cities in India. As per a company statement, Redcliffe plans to build more labs and collection centers while also expanding its home collection services network.
Strategic Developments
In addition to organic growth, Redcliffe Labs has been active in pursuing strategic acquisitions in North-Western India. The company remains focused on PAN-India expansion through both partnerships and further acquisitions.
Redcliffe Labs has also reinforced its leadership team, bringing in Ankur Shah, former Chief Finance and Strategy Officer of Careem, as an independent director. Additionally, Alka Saxena, formerly with Health Care at Home and Dr. Lal PathLabs, has joined as the company’s Chief Financial Officer.
Also Read: Schmooze, Meme-based Dating App, Raises $4 Million in Series A Funding
Founded in 2021 by Vidya Madhavan and Abhinav Anurag, Schmooze blends the power of memes with AI to create a unique dating experience.
About the Company
Founded in 2018, Redcliffe Labs was built on the mission of making quality healthcare accessible to everyone in India. Today, it offers services in more than 220 cities through a vast network of 80 labs, over 2,000 collection centers, and home collection options. The company has served over 7 million patients across tier I, II, and III cities.
Financially, Redcliffe Labs saw a remarkable increase in revenue over the past year, rising from Rs 130 crore to Rs 347 crore. However, its losses also widened from Rs 67.7 crore to Rs 345.6 crore. In the competitive diagnostics space, Redcliffe Labs contends with established players such as Thyrocare, Healthians, 1mg, and Dr. Lal PathLabs.
The fresh influx of capital will enable Redcliffe Labs to advance its growth trajectory, with a focus on expanding its footprint across India and enhancing its diagnostics services.
